<DOC>
	<DOCNO>NCT01590836</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacodynamic response ( effect investigate drug body ) insulin degludec/insulin aspart ( IDegAsp ) steady state subject type 1 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Pharmacodynamic Properties NN5401 Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 diabetes mellitus ( diagnose clinically ) least 12 month Treated multiple daily insulin injection continuous subcutaneous insulin infusion ( CSII ) least 12 month Body mass index ( BMI ) 18.028.0 kg/m^2 ( inclusive ) Glycosylated haemoglobin ( HbA1c ) maximum 9.5 % Fasting Cpeptide maximum 0.3 nmol/L Smoker ( define subject smoke 5 cigarette equivalent per day ) Not able willing refrain smoking , use nicotine gum transdermal nicotine patch inpatient period Subject donate blood plasma past month 500 mL within 3 month prior screen Surgery trauma significant blood loss ( 500 mL ) within last 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>